A Global Perspective on PDA Management in the Extremely Premature: Shifting Trend Toward Transcatheter Closure

Sathanandam, Shyam; McNamara, Patrick; Pedra, Carlos; Toyoshima, Katsuaki; Malekzadeh-Milani, Sophie; Patkai, Juliana; Baspinar, Osman; Uslu, Hasan Sinan; Promphan, Worakan; Khorana, Meera; Wang, Jieh-Neng; Lin, Yung-Chieh; Fujii, Takanari; Mainzer, Gur; Salazar-Lizárraga, David; Márquez-Gonzalez, Horacio; Popat, Himanshu; Mervis, Jonathan; Hong, Neoh Siew; Alwi, Mazeni; Wonwandee, Ratthapon; Schranz, Dietmar; Stanimir, Georgiev; Philip, Ranjit; Ing, Frank

doi:10.1016/j.jscai.2023.100968

Cited by 2 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study conducted at 19 children's hospitals in the USA revealed an 11% decrease in treatment of PDA from 2005 to 2014. Similarly, an extensive database encompassing over 61,000 preterm infants from 280 NICUs demonstrated a decline in the incidence of PDA diagnosis from 51 to 38%, a reduction in pharmacological treatment for PDA from 32 to 18%, and a 5% decrease in the PDA ligation rate when findings were compared between the two periods of 2011-2015 and 2006-2010 [31]. These changes have been witnessed across various countries worldwide [32][33][34].…”

Section: Evidence To Support Conservative Pda Treatment Approachmentioning

confidence: 97%

Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants

Chan,

Singh

2023

JCDD

View full text Add to dashboard Cite

There is no universal consensus on management of patent ductus arteriosus (PDA) in preterm infants and it varies significantly worldwide, even among the clinicians within units. The decision to treat requires a thorough understanding of the clinical status of the patient, clinical evaluation of PDA, echocardiographic diagnosis, and hemodynamic impact of ductal shunt on the pulmonary and systemic circulation. In this article, updated evidence on the efficacy and adverse effects of pharmacological treatment options and expectant management are presented, while highlighting the long-term benefits of PDA treatment remains equivocal and controversial. The authors propose a schematic targeted PDA treatment approach based on gestational and chronological age for practical clinical use, and they emphasize important future directions including advancement in PDA device closure techniques, diagnostic echo-parameters, hemodynamic evaluation to assess the impact on other organs, and understanding the long-term outcomes.

show abstract